<DOC>
	<DOCNO>NCT02099708</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy long-term administration lansoprazole ( Takepron ) therapy 12 month routine clinical setting patient receive oral non-steroidal anti-inflammatory drug ( NSAIDs )</brief_summary>
	<brief_title>Long-term Use Takepron Prevention Recurrence Gastric/Duodenal Ulcer Patients Receiving Non-steroidal Anti-inflammatory Drugs</brief_title>
	<detailed_description>This special survey long-term use ( 12 month ) lansoprazole ( Takepron ) determine incidence adverse drug reaction routine clinical setting patient receive non-steroidal anti-inflammatory drug ( NSAIDs ) . The usual adult dosage 15 mg lansoprazole administer orally daily .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>( 1 ) Patients history gastric duodenal ulcer ( 2 ) Patients require longterm use NSAIDs reason pain management rheumatoid arthritis osteoarthritis ( 3 ) Patients take oral NSAIDs start administration lansoprazole ( include patient start NSAIDs day start administration lansoprazole ) ( 1 ) Patients gastric duodenal ulcer ( active [ A1 , A2 ] heal [ H1 , H2 ] stage assess endoscopically ) start administration lansoprazole ( 2 ) Patients active upper gastrointestinal hemorrhage start administration lansoprazole ( 3 ) Patients contraindication lansoprazole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>